Categories

Share:

New Corporate Brochure

February 17, 2020

To make your choice easier and faster 4bases’ company and product information are gathered in the new brochure

Share:

Categories

More Posts

4bases’ Paper of The Month – February 2026 – Germline DNA Repair Defects Define a High-Risk Subset of Multiple Myeloma

A newly published, large case–control study shows that germline mutations in specific DNA damage response genes significantly increase the risk of developing multiple myeloma. The article appeared in

Nanopore sequencing moves towards clinical cytogenetics

Nanopore-based cytogenetic analysis is taking concrete steps toward clinical adoption. Swiss biotech 4bases, in collaboration with Alberto Magi (Professor of Bioengineering, University of Florence), has launched pilot studies

4bases’ Paper of The Month – January 2026 – Germline Genetics as a New Cornerstone of Hereditary Hematologic Diagnostics

A new large-scale study recently published in Nature Genetics highlights a paradigm shift in hereditary hematologic diagnostics, where germline genetics is becoming a key determinant in the diagnosis of clonal evolution

4bases’ Paper of The Month – December 2025 – A clinical validation of the Oxford Nanopore Technologies LRS performance with the 4bases compatible CE-IVD panels HEVA pro, CARDIO pro, BRaCA, and ClinEX Pro in genetically heterogeneous disorders

Genetic testing has advanced enormously in the past decade, mainly thanks to short-read sequencing (SRS) technologies – such as Illumina platforms – which read DNA